Lymphocyte variant hypereosinophilic syndrome with severe eosinophilic pneumonia treated with mepolizumab: a case report
Central European Journal of Immunology · 13.03.2026
DOI: 10.5114/ceji/213650 ↗Kurz gefasst
Fallbericht in der Zeitschrift Central European Journal of Immunology, online erschienen am 13.03.2026. Verfasst von Yubin Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Lymphocyte variant hypereosinophilic syndrome (L-HES) is a rare disorder characterized by immunophenotypically abnormal T lymphocytes that produce excessive eosinophilopoietic cytokines, such as interleukin 5 (IL-5). Clinically, patients with L-HES can present with manifestations involving multiple organ systems, most commonly cutaneous lesions; however, isolated single-organ involvement excluding the skin is less common. The optimal treatment for L-HES remains poorly defined. Corticosteroids (CS) are often used as first-line therapy, while other agents – such as interferon (IFN-), anti-IL-5 monoclonal antibodies, cyclosporine, and mycophenolate – are also employed in steroid- refractory cases, although no standardized treatment consensus has been established. Here, we report a rare case of L-HES presenting severe eosinophilic pneumonia (EP) as the sole manifestation. After experiencing relapses during treatment with CS and IFN-, the patient achieved a complete and favorable clinical response following initiation of low-dose mepolizumab – an anti-IL-5 monoclonal antibody – suggesting that mepolizumab may represent an effective therapeutic option for patients with L-HES complicated by EP.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Zitieren
APA
Wang, Y., Tao, Y., & Mao, H. (2026). Lymphocyte variant hypereosinophilic syndrome with severe eosinophilic pneumonia treated with mepolizumab: a case report. Central European Journal of Immunology. https://doi.org/10.5114/ceji/213650
Vancouver
Wang Y, Tao Y, Mao H. Lymphocyte variant hypereosinophilic syndrome with severe eosinophilic pneumonia treated with mepolizumab: a case report. Central European Journal of Immunology. 2026. doi:10.5114/ceji/213650
BibTeX
@article{Wang2026,
author = {Wang, Yubin and Tao, Yuhan and Mao, Hui},
title = {Lymphocyte variant hypereosinophilic syndrome with severe eosinophilic pneumonia treated with mepolizumab: a case report},
journal = {Central European Journal of Immunology},
year = {2026},
doi = {10.5114/ceji/213650}
}
EUVIMED